Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.
about
Long-term safety and efficacy of telmisartan/amlodipine single pill combination in the treatment of hypertensionRAGE mediates accelerated diabetic vein graft atherosclerosis induced by combined mechanical stress and AGEs via synergistic ERK activationHigh-glucose-induced regulation of intracellular ANG II synthesis and nuclear redistribution in cardiac myocytesEvolving pandemic diabetic nephropathyAdvanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.Central Arterial Aging and Angiotensin II Signaling.Elevated plasma chymotrypsin-like protease (chymase) activity in women with preeclampsia.Cardiovascular risk reduction with Renin-Angiotensin aldosterone system blockade.Increased urinary Angiotensinogen/Creatinine (AGT/Cr) ratio may be associated with reduced renal function in autosomal dominant polycystic kidney disease patients.Predictive value of advanced glycation end products for the development of post-infarction heart failure: a preliminary report.Tuning three-dimensional collagen matrix stiffness independently of collagen concentration modulates endothelial cell behaviorAngiotensin II up-regulates angiotensin I-converting enzyme (ACE), but down-regulates ACE2 via the AT1-ERK/p38 MAP kinase pathway.In vivo endothelial gene regulation in diabetes.Why is blood pressure so hard to control in patients with type 2 diabetes?Mast cell chymase and tryptase as targets for cardiovascular and metabolic diseases.The evolving story of the RAAS in hypertension, diabetes and CV disease: moving from macrovascular to microvascular targets.Targets of chymase inhibitors.Update on the role of angiotensin in the pathophysiology of coronary atherothrombosis.MEMBRANE TYPE 1-MATRIX METALLOPROTEINASE (MT1-MMP) IDENTIFIED AS A MULTIFUNCTIONAL REGULATOR OF VASCULAR RESPONSES.Improvement of cardiovascular remodelling by chymase inhibitor.Intracrine angiotensin II functions originate from noncanonical pathways in the human heart.Role of Tissue Renin-angiotensin System and the Chymase/angiotensin-(1-12) axis in the Pathogenesis of Diabetic Retinopathy.Combination treatment of human umbilical cord matrix stem cell-based interferon-beta gene therapy and 5-fluorouracil significantly reduces growth of metastatic human breast cancer in SCID mouse lungs.Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis.Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters.The relationship of serum AGE levels in diabetic mothers with adverse fetal outcome.Antibodies against RAGE in sepsis and inflammation: implications for therapy.Multifunctional Role of Chymase in Acute and Chronic Tissue Injury and Remodeling.Methylglyoxal further impairs adipose tissue metabolism after partial decrease of blood supply.
P2860
Q26824261-B54F5B0E-D7D3-49F0-9B23-C200FBA94EFCQ28482199-19E44BA9-3202-440D-A6A9-95BD795B5E2EQ28582700-4FB1BE2E-FA54-42D3-A34E-42AB2C89FB37Q30352538-DAECF952-5D6E-47FB-9361-4ED0AFE8A0C8Q33711306-D50E6D81-CBEB-492A-B2EF-5FEF686F4F8AQ34681004-E13C4B64-E26F-44DE-A23C-98DE0535312EQ34707028-A661D64E-B3CA-411B-A590-22125F2FC3C9Q35203083-A0884557-E761-4915-BAA4-4F328F328E63Q35669323-F61AC322-656C-4CE0-B935-616A524F67ABQ36373255-184ABECC-8B50-4E9E-B096-C7EC98DB71F8Q36428268-A1891DFC-C9DF-407F-B431-75D0D7095194Q36579769-F0095EBA-3CED-461A-915A-7EBEA4A8B33CQ36628496-60AE7823-EC98-4179-9C63-C2067FB7A11EQ36904456-4409FBCA-E631-4333-8E38-7F97DE533D99Q37578873-6D1D5D3E-F1AE-46E3-BBCD-5336FD66F952Q37611981-C9BF4BDD-300C-43A8-AAFA-85331A9B17CFQ37835286-B3D8AFE6-0D8E-4F7A-A0BC-4B2D76428640Q38317550-BE6BADDE-3EBD-49DD-B89F-C81DD26A5EA0Q38586884-84A26A9D-D6B5-49AA-A87D-5DBFD4989B45Q38707728-3FA626F0-7936-4646-B574-24E2F24B1B0BQ38846247-46F980A3-1ED3-468C-85D3-4A0F9F8A5C9EQ39238324-49A9C335-F59A-47AF-91B3-9CB3E3767BF8Q39963975-0AA85863-0449-4D00-8FAD-FD60F0926FB1Q42160141-478869DC-52BF-4B8E-BF29-216697ACFEBEQ42873491-C673DBD3-4513-44ED-9A1F-31DB71467EFEQ44478965-4BB083D0-828A-4CCE-A603-39925E4BC913Q47574722-3CF304D2-6217-42A9-BC90-2502D326847AQ47652218-549186BD-4314-4621-BFE7-5FE93813FD97Q51337776-5705AA55-CFEC-4A63-9F05-C09742B08EFF
P2860
Advanced glycation end products activate a chymase-dependent angiotensin II-generating pathway in diabetic complications.
description
2006 nî lūn-bûn
@nan
2006 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի մարտին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Advanced glycation end product ...... way in diabetic complications.
@ast
Advanced glycation end product ...... way in diabetic complications.
@en
Advanced glycation end product ...... way in diabetic complications.
@nl
type
label
Advanced glycation end product ...... way in diabetic complications.
@ast
Advanced glycation end product ...... way in diabetic complications.
@en
Advanced glycation end product ...... way in diabetic complications.
@nl
prefLabel
Advanced glycation end product ...... way in diabetic complications.
@ast
Advanced glycation end product ...... way in diabetic complications.
@en
Advanced glycation end product ...... way in diabetic complications.
@nl
P2093
P2860
P1433
P1476
Advanced glycation end product ...... way in diabetic complications.
@en
P2093
Luan D Truong
Shokei Kim-Mitsuyama
Vijay Koka
Wansheng Wang
Xiao Ru Huang
P2860
P304
P356
10.1161/CIRCULATIONAHA.105.575589
P407
P577
2006-03-06T00:00:00Z